Posted: May 3, 2007
According to the Acomplia Report, "It's now official. If diet drug Acomplia (rimonabant) is ultimately approved for sale in the United States, the prescription diet pill will go on the U.S. market not as Acomplia but as Zimulti."
While this is bad news for the Acomplia Report, which will have to change it's name, I guess, and is perhaps a mild setback for Sanofi-Aventis, which plans to market the diabetes drug in the US, it is definitely good news for bloggers.
I think it's a great name for an Italian dessert, which makes the name much more ironic because sugary desserts may be the last thing a diabetes/obesity drug name should conjure up in the minds of patients.
For more, plus a graphic illustrating the New Zimulti Dessert, see today's post to Pharma Marketing Blog.
For more posts in related topic areas, see:
If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
| Return to Pharma Marketing Blog Topics |